TL;DR
Multimodal PET imaging reveals dynamic interactions between cerebral glucose metabolism and dopaminergic degeneration in Parkinson’s disease, highlighting cerebellar-pontine hypermetabolism as a compensatory response to nigrostriatal degeneration.
BACKGROUND Understanding the heterogeneity of Parkinson's disease (PD) is essential to guide patient care, prognosis, and treatment. OBJECTIVE We used 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET), 18F-N-(3-fluoropropyl)-2β-carbomethoxy-3β-(4-iodophenyl) nortropane (18F-FP-CIT) PET, and Subtype...
OBJECTIVE Scans Without Evidence of Dopaminergic Deficit (SWEDD) refers to individuals with Parkinsonian symptoms but no presynaptic dopaminergic deficit on dopamine transporter (DAT) imaging. Given its likely heterogeneity, we used a multimodal imaging approach to compare SWEDD with Parkinson's disease (PD) and health...
Despite well-established clinical diagnostic criteria for Parkinson's disease (PD), challenges remain in early-stage diagnosis, differentiating atypical parkinsonism disorders, and understanding of underlying disease mechanisms. Neuroimaging, particularly positron emission tomography (PET) with [18F]fluorodeoxyglucose...
Quantitative T1 mapping (qT1) is a magnetic resonance imaging (MRI) biomarker of brain microstructural changes; however, its application in Alzheimer disease (AD) remains limited. We compared cortico-limbic qT1 values between patients with AD and healthy controls (HCs) and examined their relationship with amyloid burde...
Purpose Dynamic [11C]UCB-J PET can simultaneously provide information about synaptic density and relative perfusion in Parkinson's disease (PD). We investigated whether these complementary biomarkers could explain a higher percentage of motor symptom severity variation in PD and inform other PD-specific physiological a...
Parkinsonian syndromes comprise overlapping neurodegenerative and non-degenerative disorders, making aetiological diagnosis difficult, while existing procedural guidance does not fully integrate tracer-specific biology with clinical decision-making, multimodal strategies, and emerging quantitative and pathology-directe...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
